Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17827886 | 0.90 | KDM4E (0.42) | KDM4EHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17827884 | 0.82 | GRIN2B (0.35) | KDM4EHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL17827885 | 0.80 | KDM4E (0.35) | KDM4E | |
| SCHEMBL17827888 | 0.74 | ALDH1A1 (0.43) | KDM4EHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17827882 | 0.70 | KDM4E (0.36) | KDM4EALDH1A1 | |
| SCHEMBL25997319 | 0.70 | HRH3 (0.50) | KDM4ESMN1; SMN2L3MBTL1 | |
| SCHEMBL18595229 | 0.70 | HRH3 (0.50) | KDM4EHTTSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL14426347 | 0.69 | LTA4H (0.59) | KDM4EHTTSMN1; SMN2TDP1 | |
| SCHEMBL17921665 | 0.69 | MEN1 (0.44) | KDM4EHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL26003876 | 0.68 | HRH3 (0.65) | KDM4EHTTSMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | KDM4E 2666/4885HTT 3547/4885SMN1; SMN2 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.